Abstract
Please check the hierarchy of the section headings and correct if necessary.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Werling RW, Yaziji H, Bacchi CE, Gown AM. CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas. Am J Surg Pathol. 2003;27:303–10.
Mazziotta RM, Borczuk AC, Powell CA, et al. CDX2 immunostaining as a gastrointestinal marker: expression in lung carcinomas is a potential pitfall. Appl Immunohistochem Mol Morphol. 2005;13:55–60.
Levine PH, Joutovsky A, Cangiarella J, et al. CDX-2 expression in pulmonary fine-needle aspiration specimens: a useful adjunct for the diagnosis of metastatic colorectal adenocarcinoma. Diagn Cytopathol. 2006;34:191–5.
Lin X, Saad RS, Luckasevic TM, et al. Diagnostic value of CDX-2 and TTF-1 expressions in separating metastatic neuroendocrine neoplasms of unknown origin. Appl Immunohistochem Mol Morphol. 2007;15:407–14.
Li Z, Zhou K, Mei K, et al. SATB2 is a highly sensitive marker for hindgut well differentiated neuroendocrine tumors. Mod Pathol. 2013;26(S2):164A.
Magnusson K, de Wit M, Brennan DJ, et al. SATB2 in combination with Cytokeratin 20 identifies over 95% of all colorectal carcinomas. Am J Surg Pathol. 2011;35(7):937–48.
Dragomir A, de Wit M, Johansson C, et al. The role of SATB2 as a diagnostic marker for tumors of colorectal origin: Results of a pathology-based clinical prospective study. Am J Clin Pathol. 2014;141(5):630–8.
Su MC, Yuan RH, Lin CY. Cadherin 17 is a useful diagnostic marker for adenocarcinomas of the digestive system. Mod Pathol. 2008;21(11):1379–86.
Panarelli NC, Yantiss RK, Yeh MM, et al. Tissue-specific cadherin CDH17 is a useful marker of gastrointestinal adenocarcinomas with higher sensitivity than CDX2. Am J Clin Pathol. 2012;138(2):211–22.
Nakagawa K, Matsuno Y, Kunitoh H, et al. Immunohistochemical KIT (CD117) expression in thymic epithelial tumors. Chest. 2005;128:140–4.
Miselli F, Millefanti C, Conca E, et al. PDGFRA immunostaining can help in the diagnosis of gastrointestinal stromal tumors. Am J Surg Pathol. 2008;32:738–43.
Heim-Hall J, Yohe L. Application of immunohistochemistry to soft tissue neoplasms. Arch Pathol Lab Med. 2008;132:476–89.
Rossi G, Villi R, Bertolini F, et al. PDGFR expression in differential diagnosis between KIT–negative gastrointestinal stromal tumours and other primary soft-tissue tumours of the gastrointestinal tract. Histopathology. 2005;46(5):522–31.
Xiaohui Z, Changjun Y. Gastrointestinal stroma tumor. J Gastrointest Oncol. 2012;3(3):189–208.
Espinosa I, Lee C-H, Kim MK, et al. A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors. Am J Surg Pathol. 2008;32:210–8.
Miettinen M, Wang Z-F, Lasot WJ. DOG1 Antibody in the differential diagnosis of gastrointestinal stromal tumors. A study of 1840 cases. Am J Surg Pathol. 2009;33:1401–8.
Liegl B, Hornick JL, Corless CL, et al. Monoclonal antibody DOG1.1 shows higher sensitivity than KIT in the diagnosis of gastrointestinal stromal tumors, including unusual subtypes. Am J Surg Pathol. 2009;33:437–46.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG
About this chapter
Cite this chapter
Tuffaha, M.S.A., Guski, H., Kristiansen, G. (2018). Markers and Immunoprofile of Tumors of the Gastrointestinal Tract. In: Immunohistochemistry in Tumor Diagnostics. Springer, Cham. https://doi.org/10.1007/978-3-319-53577-7_7
Download citation
DOI: https://doi.org/10.1007/978-3-319-53577-7_7
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-53576-0
Online ISBN: 978-3-319-53577-7
eBook Packages: MedicineMedicine (R0)